title: Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.
abstract: Human African trypanosomiasis (HAT) is caused by the protozoan parasite Trypanosoma brucei, and the disease is fatal if untreated. There is an urgent need to develop new, safe and effective treatments for HAT because current drugs have extremely poor safety profiles and are difficult to administer. Here we report the development and application of a cell-based resazurin reduction assay for high throughput screening and identification of new inhibitors of T. b. brucei as starting points for the development of new treatments for human HAT. Active compounds identified in primary screening of ∼48,000 compounds representing ∼25 chemical classes were titrated to obtain IC50 values. Cytotoxicity against a mammalian cell line was determined to provide indications of parasite versus host cell selectivity. Examples from hit series that showed selectivity and evidence of preliminary SAR were re-synthesized to confirm trypanocidal activity prior to initiating hit-to-lead expansion efforts. Additional assays such as serum shift, time to kill and reversibility of compound effect were developed and applied to provide further criteria for advancing compounds through the hit-to-lead phase of the project. From this initial effort, six distinct chemical series were selected and hit-to-lead chemistry was initiated to synthesize several key analogs for evaluation of trypanocidal activity in the resazurin-reduction assay for parasite viability. From the hit-to-lead efforts, a series was identified that demonstrated efficacy in a mouse model for T. b. brucei infection and was progressed into the lead optimization stage. In summary, the present study demonstrates the successful and effective use of resazurin-reduction based assays as tools for primary and secondary screening of a new compound series to identify leads for the treatment of HAT.
authors.affiliation: SCYNEXIS Inc., P.O. Box 12878, Research Triangle Park, NC 27709-2878, United States.
authors.forename: Tana
authors.initials: T
authors.lastname: Bowling
authors.affiliation: SCYNEXIS Inc., P.O. Box 12878, Research Triangle Park, NC 27709-2878, United States.
authors.forename: Luke
authors.initials: L
authors.lastname: Mercer
authors.affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
authors.forename: Robert
authors.initials: R
authors.lastname: Don
authors.affiliation: SCYNEXIS Inc., P.O. Box 12878, Research Triangle Park, NC 27709-2878, United States.
authors.forename: Robert
authors.initials: R
authors.lastname: Jacobs
authors.affiliation: SCYNEXIS Inc., P.O. Box 12878, Research Triangle Park, NC 27709-2878, United States.
authors.forename: Bakela
authors.initials: B
authors.lastname: Nare
keywords: High throughput screening; Hit-to-lead; Time to kill; Trypanosoma brucei brucei